# A Clinical Study to Evaluate Injection TQB2102 for the Treatment of Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Progressed After Treatment With Oxal

Source: https://onco.cc/trials/nct07483684/  
OnCo record `nct07483684` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial in colorectal cancer, run by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd., not yet recruiting.

## Summary

A Clinical Study to Evaluate Injection TQB2102 for the Treatment of Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Progressed After Treatment With Oxaliplatin, Irinotecan and Fluoropyrimidine-Based Drugs is a phase 3, randomised interventional study registered as NCT07483684 by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd., with a registry enrolment figure of 142 participants, started 2026-03 and due to reach its primary completion in 2027-08. Interventions recorded: TQB2102 Injection; Trifluridine /Tipiracil (TAS-102) tablets / Fruquintinib / Regorafenib tablets. Conditions listed: HER2 IHC3+ Advanced Colorectal Cancer. Primary outcome: Progression-Free Survival (PFS) assessed by IRC based on RECIST v1.1. Colorectal eligibility wording from the registry: "* Subjects with histologically or cytologically confirmed advanced colorectal cancer". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT07483684
- Phase: 3
- Setting: A Randomized, Open-Label, Active-Controlled, Multicenter Phase III Clinical Study to Evaluate Injection TQB2102 Versus Investigator's Choice of Treatment Regimens in Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Progressed After Treatment With Oxaliplatin, Irinotecan and Fluoropyrimidine-Based Drugs
- Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- Enrolled: 142

## Sources

- ClinicalTrials.gov NCT07483684: https://clinicaltrials.gov/study/NCT07483684

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [HER2-amplified colorectal cancer](https://onco.cc/cancers/her2-amplified-colorectal/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- companies: [Sino Biopharmaceutical (Chia Tai Tianqing)](https://onco.cc/companies/sino-biopharm/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07483684.json